Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Previously-Treated Metastatic Colorectal Cancer
NCT00504153Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2007
- Primary completion
- Jun 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Started Jul 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00504153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504153.